Nevro price target raised to $72 from $67 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on Nevro to $72 from $67 and keeps a Buy rating on the shares. The analyst updated his model and lifted our Q4 sales estimates to match the preannouncement and lowered our 2023 and forward revenue estimates to reflect 2023 guidance.